News Immunomedics wows ESMO with breast cancer data reveal Immunomedics has revealed the trial data that convinced Gilead to stage a
Views & Analysis ESMO 2019 roundup The European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma companies choosing it as a forum to reveal their latest studies.
News ESMO 2019 – new data could unlock bigger market for PARP inh... AstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as first-l
News ESMO 2019 - Amgen’s KRAS drug finds colorectal cancer a chal... Amgen’s KRAS inhibitor AMG 510 has shown little effect in colorectal cancer patients, according to new data reported at the
Views & Analysis Merck KGaA's bold new approach to cancer immunotherapy Germany’s Merck KGaA is hoping to stand out from the crowd with a bold new approach to cancer immunotherapy.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
